Literature DB >> 26391933

Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department.

Patricia L Kavanagh1, Philippa G Sprinz2, Tahlia L Wolfgang2, Kelly Killius3, Maria Champigny4, Amy Sobota2, David Dorfman2, Karan Barry5, Renee Miner5, James M Moses2.   

Abstract

OBJECTIVES: Vaso-occlusive episodes (VOEs) account for the majority of emergency department (ED) visits for children with sickle cell disease (SCD). We hypothesized that addressing key barriers to VOE care would improve receipt of analgesics and outcomes.
METHODS: A quality improvement (QI) initiative was conducted from September 2010 to April 2014 to streamline VOE care in an urban pediatric ED. Four interventions were used: a standardized time-specific VOE protocol; intranasal fentanyl as the first parenteral pain medication; an SCD pain medication calculator; and provider and patient/family education. Data were collected for 3 outcome measures (mean time from triage to first parenteral opioid and admission/discharge decision, and proportion discharged from the ED); 1 process measure (mean time from triage to initiation of patient-controlled analgesia); and 4 balancing measures (mean time from triage to second intravenous opioid dose, 24-hour ED readmission, respiratory depression, and length of stay).
RESULTS: There were 289 ED visits in the study period. Improvements were seen in mean time to: first dose of parenteral opioid (56 to 23 minutes); second opiate intravenous dose (106 to 83 minutes); admission and discharge decisions (163 to 109 minutes and 271 to 178 minutes, respectively); and initiation of patient-controlled analgesia (216 to 141 minutes). The proportion discharged from the ED increased from 32% to 48% (χ(2) = 6.5402, P = .01). No increase in 24-hour readmission, respiratory depression, or inpatient length of stay was observed.
CONCLUSIONS: Using VOE-specific interventions, we significantly improved VOE care for children. Studies are needed to determine if these results can be replicated.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26391933     DOI: 10.1542/peds.2014-3470

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

2.  Intravenous morphine titration vs. oral hydrocodone/acetaminophen for adults with lower extremity displaced fracture in an emergency department setting: A randomized controlled trial.

Authors:  Zhengqi Pan; Yongjian Qi; Yinxian Wen; Liaobin Chen
Journal:  Exp Ther Med       Date:  2018-08-14       Impact factor: 2.447

3.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

Review 4.  Improving Emergency Department-Based Care of Sickle Cell Pain.

Authors:  Jeffrey A Glassberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.

Authors:  Jason Payne; Inmaculada Aban; Lee M Hilliard; Jennifer Madison; Christina Bemrich-Stolz; Thomas H Howard; Amanda Brandow; Emily Waite; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

6.  A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).

Authors:  Paula Tanabe; Susan Silva; Hayden B Bosworth; Regina Crawford; Judith A Paice; Lynne D Richardson; Christopher N Miller; Jeffrey Glassberg
Journal:  Am J Hematol       Date:  2017-11-10       Impact factor: 10.047

Review 7.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

8.  Exploring Emergency Department Provider Experiences With and Perceptions of Weight-Based Versus Individualized Vaso-Occlusive Treatment Protocols in Sickle Cell Disease.

Authors:  LaʼKita M J Knight; Elijah O Onsomu; Hayden B Bosworth; Regina D Crawford; Theresa DeMartino; Jeffrey Glassberg; Judith A Paice; Christopher N Miller; Lynne Richardson; Paula Tanabe
Journal:  Adv Emerg Nurs J       Date:  2019 Jan/Mar

Review 9.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 10.  Managing Pediatric Pain in the Emergency Department.

Authors:  Benoit Bailey; Evelyne D Trottier
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.